Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements towards New Perspectives.

Details

Ressource 1Download: 31205470_BIB_70A914BCFC4C.pdf (1240.44 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_70A914BCFC4C
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements towards New Perspectives.
Journal
Journal of oncology
Author(s)
De Goycoechea D., Stalder G., Martins F., Duchosal M.A.
ISSN
1687-8450 (Print)
ISSN-L
1687-8450
Publication state
Published
Issued date
2019
Peer-reviewed
Oui
Volume
2019
Pages
9513701
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Abstract
Immune checkpoint inhibition (ICI) became one of the major breakthroughs in cancer treatment over the past decade and entered into therapy within standard oncohematology practice. ICI has demonstrated impressive response rates as salvage therapy in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) and is now being tested as an adjunction to chemotherapy in the frontline settings. CHL exquisite sensitivity to PD-1/PD-L1 axis inhibition relies on a particular biological background. By contrast, non-Hodgkin lymphomas (NHL) have demonstrated heterogeneous response rates using ICI. These observations highlight discrepancies between various types of lymphomas in terms of genetic alterations, immune microenvironment interactions, and disease phenotype. This review aims to focus on cHL immune escape mechanisms, focusing on cHL biological sensitivity to PD-1 blockade. We will summarize the available data issued from clinical trials on ICI in cHL and its safety profile. Going beyond the current use of monoclonal antibodies (mAb) targeting immune checkpoints in clinical practice, we will offer an overview of new combinatory therapeutic perspectives where cHL immunotherapy may be considered.
Pubmed
Web of science
Open Access
Yes
Create date
24/06/2019 10:25
Last modification date
15/01/2021 7:10
Usage data